124 related articles for article (PubMed ID: 20409526)
21. EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer.
Dubey S; Stephenson P; Levy DE; Miller JA; Keller SM; Schiller JH; Johnson DH; Kolesar JM;
J Thorac Oncol; 2006 Jun; 1(5):406-12. PubMed ID: 17409891
[TBL] [Abstract][Full Text] [Related]
22. Serine protease inhibitor Kazal type 1 and epidermal growth factor receptor are expressed in pancreatic tubular adenocarcinoma, intraductal papillary mucinous neoplasm, and pancreatic intraepithelial neoplasia.
Ozaki N; Ohmuraya M; Ida S; Hashimoto D; Ikuta Y; Chikamoto A; Hirota M; Baba H
J Hepatobiliary Pancreat Sci; 2013 Aug; 20(6):620-7. PubMed ID: 23475261
[TBL] [Abstract][Full Text] [Related]
23. Expression of estrogen receptor beta correlates with adverse prognosis in resected pancreatic adenocarcinoma.
Seeliger H; Pozios I; Assmann G; Zhao Y; Müller MH; Knösel T; Kreis ME; Bruns CJ
BMC Cancer; 2018 Oct; 18(1):1049. PubMed ID: 30373552
[TBL] [Abstract][Full Text] [Related]
24. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors.
Berry W; Algar E; Kumar B; Desmond C; Swan M; Jenkins BJ; Croagh D
Int J Cancer; 2017 May; 140(10):2331-2343. PubMed ID: 28198009
[TBL] [Abstract][Full Text] [Related]
25. EGFR Mutated Lung Adenocarcinoma Metastasis to the Pancreas Mimicking Primary Pancreatic Ductal Carcinoma.
Cao C; Kong MX; Kapali M; Moezardalan K; Shi Q; Azarm A; Lai J
Anticancer Res; 2020 Aug; 40(8):4401-4404. PubMed ID: 32727769
[TBL] [Abstract][Full Text] [Related]
26. Additive clinical impact of epidermal growth factor receptor and podocalyxin-like protein expression in pancreatic and periampullary adenocarcinomas.
Heby M; Karnevi E; Elebro J; Nodin B; Eberhard J; Saukkonen K; Hagström J; Mustonen H; Seppänen H; Haglund C; Jirström K; Larsson AH
Sci Rep; 2020 Jun; 10(1):10373. PubMed ID: 32587323
[TBL] [Abstract][Full Text] [Related]
27. Prognostic implications of routine, immunohistochemical, and molecular staging in resectable pancreatic adenocarcinoma.
Niedergethmann M; Rexin M; Hildenbrand R; Knob S; Sturm JW; Richter A; Post S
Am J Surg Pathol; 2002 Dec; 26(12):1578-87. PubMed ID: 12459624
[TBL] [Abstract][Full Text] [Related]
28. R497K polymorphism in epidermal growth factor receptor gene is associated with the risk of acute coronary syndrome.
Gao LB; Zhou B; Zhang L; Wei YS; Wang YY; Liang WB; Lv ML; Pan XM; Chen YC; Rao L
BMC Med Genet; 2008 Jul; 9():74. PubMed ID: 18664296
[TBL] [Abstract][Full Text] [Related]
29. Molecular Analysis of Vascular Endothelial Growth Factor (VEGF) Receptors in EUS-guided Samples Obtained from Patients with Pancreatic Adenocarcinoma.
Costache MI; Iordache S; Costache CA; Dragos E; Dragos A; Saftoiu A
J Gastrointestin Liver Dis; 2017 Mar; 26(1):51-57. PubMed ID: 28338114
[TBL] [Abstract][Full Text] [Related]
30. Mutations of the EGFR, K-ras, EML4-ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma.
Ohba T; Toyokawa G; Osoegawa A; Hirai F; Yamaguchi M; Taguchi K; Seto T; Takenoyama M; Ichinose Y; Sugio K
Surg Today; 2016 Sep; 46(9):1091-8. PubMed ID: 26711128
[TBL] [Abstract][Full Text] [Related]
31. High expression of E-cadherin in pleural effusion cells predicts better prognosis in lung adenocarcinoma patients.
Zhao C; Li X; Su C; Li J; Cheng N; Ren S; Chen X; Zhou C
Int J Clin Exp Pathol; 2015; 8(3):3104-9. PubMed ID: 26045824
[TBL] [Abstract][Full Text] [Related]
32. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.
Kosaka T; Yatabe Y; Onozato R; Kuwano H; Mitsudomi T
J Thorac Oncol; 2009 Jan; 4(1):22-9. PubMed ID: 19096302
[TBL] [Abstract][Full Text] [Related]
33. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma.
Ueda S; Ogata S; Tsuda H; Kawarabayashi N; Kimura M; Sugiura Y; Tamai S; Matsubara O; Hatsuse K; Mochizuki H
Pancreas; 2004 Jul; 29(1):e1-8. PubMed ID: 15211117
[TBL] [Abstract][Full Text] [Related]
34. Coexpression of EGFR and HER-2 in pancreatic ductal adenocarcinoma: a comparative study using immunohistochemistry correlated with gene amplification by fluorescencent in situ hybridization.
Dancer J; Takei H; Ro JY; Lowery-Nordberg M
Oncol Rep; 2007 Jul; 18(1):151-5. PubMed ID: 17549361
[TBL] [Abstract][Full Text] [Related]
35. K-Ras and microsatellite marker analysis of fine-needle aspirates from intraductal papillary mucinous neoplasms of the pancreas.
Schoedel KE; Finkelstein SD; Ohori NP
Diagn Cytopathol; 2006 Sep; 34(9):605-8. PubMed ID: 16900481
[TBL] [Abstract][Full Text] [Related]
36. High expression of plasminogen activator inhibitor-2 (PAI-2) is a predictor of improved survival in patients with pancreatic adenocarcinoma.
Smith R; Xue A; Gill A; Scarlett C; Saxby A; Clarkson A; Hugh T
World J Surg; 2007 Mar; 31(3):493-502; discussion 503. PubMed ID: 17219285
[TBL] [Abstract][Full Text] [Related]
37. Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study.
Nahm CB; Turchini J; Jamieson N; Moon E; Sioson L; Itchins M; Arena J; Colvin E; Howell VM; Pavlakis N; Clarke S; Samra JS; Gill AJ; Mittal A
Eur J Surg Oncol; 2019 Feb; 45(2):218-224. PubMed ID: 30348604
[TBL] [Abstract][Full Text] [Related]
38. Association of the EGFR intron 1 CA repeat length with lung cancer risk.
Zhang W; Weissfeld JL; Romkes M; Land SR; Grandis JR; Siegfried JM
Mol Carcinog; 2007 May; 46(5):372-80. PubMed ID: 17219440
[TBL] [Abstract][Full Text] [Related]
39. Shorter EGFR Dinucleotide Repeat Length Predicts Better Response of Patients with Advanced Non-small Cell Lung Cancer to EGFR Tyrosine Kinase Inhibitor.
Chen B; Luo J; Gu W; Shen L; Wang H; Zhou S
Cell Biochem Biophys; 2015 Dec; 73(3):799-804. PubMed ID: 27259328
[TBL] [Abstract][Full Text] [Related]
40. Global profiling of EGFR gene mutation, amplification, regulation and tissue protein expression in unknown primary carcinomas: to target or not to target?
Dova L; Pentheroudakis G; Georgiou I; Malamou-Mitsi V; Vartholomatos G; Fountzilas G; Kolaitis N; Kitsiou E; Pavlidis N
Clin Exp Metastasis; 2007; 24(2):79-86. PubMed ID: 17390112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
